The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-01 and is reviewed periodically as new material appears.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Disability and even deaths from excessive use of these products have been claimed. The U.S. Food and Drug Administration (FDA) states that zinc damages nerve receptors in the nose, causing anosmia. Reports of anosmia were also observed in the 1930s when zinc preparations were used in a failed attempt to prevent polio infections. On June 16, 2009, the FDA ordered removal of zinc-based intranasal cold products from store shelves. The FDA said the loss of smell can be life-threatening because people with impaired smell cannot detect leaking gas or smoke, and cannot tell if food has spoiled before they eat it. Recent research suggests that the topical antimicrobial zinc pyrithione is a potent heat shock response inducer that may impair genomic integrity with induction of PARP-dependent energy crisis in cultured human keratinocytes and melanocytes.
However, forceful actions by the United States against Apartheid South Africa were diminished under President Reagan as the Reagan administration feared the rise of revolution in South Africa as had happened in Zimbabwe against white minority rule. In 1979, the Soviet Union intervened in Afghanistan to establish a communist state (existed until 1992), although the act was seen as an invasion by the West which responded to the Soviet military actions by boycotting the Moscow Olympics of 1980 and providing clandestine support to the Mujahideen, including Osama bin Laden, as a means to challenge the Soviet Union. The war became a Soviet equivalent of the Vietnam War to the United States and it remained a stalemate throughout the 1980s.
=== Neuron survival === Binding interaction between NGF and the TrkA receptor facilitates receptor dimerization and tyrosine residue phosphorylation of the cytoplasmic tail by adjacent Trk receptors. Trk receptor phosphorylation sites operate as Shc adaptor protein docking sites, which undergo phosphorylation by the TrkA receptor Once the cytoplasmic adaptor protein (Shc) is phosphorylated by the receptor cytoplasmic tail, cell survival is initiated through several intracellular pathways. One major pathway leads to the activation of the serine/threonine kinase, Akt. This pathway begins with the Trk receptor complex-recruitment of a second adaptor protein called growth factor-receptor bound protein-2 (Grb2) along with a docking protein called Grb2-associated Binder-1 (GAB1). Subsequently, phosphatidylinositol-3 kinase (PI3K) is activated, resulting in Akt kinase activation. Study results have shown that blocking PI3K or Akt activity results in death of sympathetic neurons in culture, regardless of NGF presence. However, if either kinase is constitutively active, neurons survive even without NGF. A second pathway contributing to cell survival occurs through activation of the mitogen-activated protein kinase (MAPK) kinase. In this pathway, recruitment of a guanine nucleotide exchange factor by the adaptor and docking proteins leads to activation of a membrane-associated G-protein known as Ras. The guanine nucleotide exchange factor mediates Ras activation through the GDP-GTP exchange process.
==== Antihormonal activity ==== As an antiandrogen, ketoconazole operates through at least two mechanisms of action. First, and most notably, high oral doses of ketoconazole (e.g. 400 mg three times per day) block both testicular and adrenal androgen biosynthesis, leading to a reduction in circulating testosterone levels. It produces this effect through inhibition of 17α-hydroxylase and 17,20-lyase, which are involved in the synthesis and degradation of steroids, including the precursors of testosterone. Due to its efficacy at reducing systemic androgen levels, ketoconazole has been used with some success as a treatment for androgen-dependent prostate cancer. Second, ketoconazole is an androgen receptor antagonist, competing with androgens such as testosterone and dihydrotestosterone (DHT) for binding to the androgen receptor. This effect is thought to be quite weak however, even with high oral doses of ketoconazole. Ketoconazole, along with miconazole, has been found to act as an antagonist of the glucocorticoid receptor. Ketoconazole is a racemic mixture consisting of cis-(2S,4R)-(−) and cis-(2R,4S)-(+) enantiomers. The cis-(2S,4R) isomer was more potent in inhibiting progesterone 17α,20-lyase than its enantiomer (IC50 values of 0.05 and 2.38 μM, respectively) and in inhibiting 11β-hydroxylase (IC50 values of 0.152 and 0.608 μM, respectively). Both isomers were relatively weak inhibitors of human placental aromatase. Oral ketoconazole has been used clinically as a steroidogenesis inhibitor in men, women, and children at dosages of 200 to 1,200 mg/day.
Sources: en.wikipedia.org
Bassinger reprised the role of Stargirl in the ninth episode of the fourth season of the HBO Max series Titans, titled "Dude, Where's My Gar?"; that series exists on Earth-9 of the live action multiverse.
==== Unanimous selection for Most Valuable Player Award (1994) ==== The most productive season in Bagwell's professional career was the strike-shortened 1994 season which set several franchise records. On Opening Day, April 4, against the Montreal Expos, Bagwell hit the game-tying home run while going 3-for-6 as the Astros won in a 12-inning walk-off. For the month of April, he batted .360 with six home runs and added another six home runs in May. In June, he hit 13 home runs, establishing an Astros' franchise record for one month, while batting .394, 11 doubles, .455 OBP, .899 SLG, and 1.354 OPS. On June 24, in a 16–4 rout of the Los Angeles Dodgers at the Astrodome, he hit three home runs, including two in the same inning, becoming the first Astro since Glenn Davis in 1990 to do so. Bagwell was the NL Player of the Week for consecutive weeks on June 19 and June 26 and the NL Player of the Month for June, his second career monthly award. Selected to his first All-Star Game as a reserve, Bagwell had tied Kirby Puckett for the major league RBI lead at 81 going into the All-Star break, and batted .348 with 27 home runs and 74 runs scored. In the All-Star Game, Bagwell entered as a pinch hitter for starting pitcher Greg Maddux, singling off David Cone, and wound up collecting two hits in four at bats. The first player in the majors to reach 100 RBI on July 27, Bagwell homered off José Rijo in a 6–5 win over Cincinnati to give him 101 RBI in his first 101 games. In July, he tied a club record for RBI in any month with 29, which José Cruz and Jimmy Wynn shared.
=== Cluster headaches === Preventive therapy with verapamil is believed to work because it has an effect on the circadian rhythm and on CGRPs, as CGRP-release is controlled by voltage-gated calcium channels.
== Research == The best known CCK receptor antagonist is the non-selective antagonist proglumide, which blocks both CCKA and CCKB receptors, and was originally developed for the treatment of stomach ulcers. This action derived from its blockade of CCKA receptor in the gut and consequent reduction in secretion of gastric acid, however a side effect of proglumide was found, namely that it increases the analgesic effects of opioid painkillers, and decreases the development of tolerance. This was subsequently found to result from its blockade of CCKB receptors in the brain. Another CCK receptor antagonist is benzotript, which is likewise non-selective. Newer drugs have since been developed which are selective for one or other of the CCK receptors. Selective CCKA receptor antagonists such as lorglumide and devazepide have been developed both for their anti-ulcer effects and as potential drugs to limit the development of gastrointestinal cancers such as colon cancer. A centrally selective antagonist—Ranquilon—has recently undergone clinical approval for the treatment of anxiety in Russia. The main focus of CCK receptor antagonist research has focused on the development of selective CCKB receptor antagonists as novel medications which have been primarily investigated for the treatment of anxiety and panic attacks, as well as for other roles such as analgesic effects.
== Background == Microtox was developed by Azur Environmental (formerly Microbics Corporation) in 1979 as a cost-effective alternative to toxicity tests available at the time. Prior to Microtox, the majority of toxicity tests available for water specifically focused on fish and daphnids. Since its inception, Microtox has become a standard method for testing the toxicity of water as well as other substrates such as soils and sediments. In recent years the Microtox technology and name have undergone various different ownerships. In 2011, Microtox and related technologies was acquired by Modern Water from Strategic Diagnostics Incorporated (SDIX) for approximately $4.5 million. Prior to SDIX, Microtox was owned by its original developers Azur Environmental. Microtox utilizes a bioluminescent bacteria (Allivibrio fischeri) to determine the toxicity of a particular substance and/or substrate. During cellular metabolism, these bacteria naturally emit light as a part of cellular respiration, which can be measured as luminescence. When exposed to toxic substances, a decrease in luminescence can be observed and percent change in luminescence can be directly correlated to toxicity. Allivibrio fischeri were specifically chosen, as these bacteria could be preserved by freeze-drying to increase shelf life and use. Both solid phase (soils and sediment) and aqueous acute toxicity testing (described below) can be conducted using this technology.
Sources: en.wikipedia.org
==== Amidation ==== HA can be conjugated with polymers and probes at the carboxyl group using an amidation reaction involving 1-ethyl-3-[3-(dimethylamino)-propyl]-carbodiimide (EDC) and N-Hydroxysuccinimide (NHS). This reaction occurs in water and is used to form more hydrolysis-resistant, non-rearrangeable intermediates that prevent the formation of the irreversible N-acyl urea byproduct, preventing amide bond formation. The amide group in this reaction can also be modified to contain a thiol group, which allows thiols to be covalently linked to HA. Thiol modification can improve many HA properties such as biocompatibility, permeation, and sustained release of a drug. This is because in the presence of biological components, thiols display a great amount of chemo-selectivity and ability to cross-link.
== Further reading == "Becker Muscular Dystrophy (for Parents)." Edited by Mena T. Scavina, KidsHealth, The Nemours Foundation, Mar. 2018, kidshealth.org/en/parents/becker-md.html. Gaudio, Daniela del; Yang, Yaping; Boggs, Barbara A.; Schmitt, Eric S.; Lee, Jennifer A.; Sahoo, Trilochan; Pham, Hoang T.; Wiszniewska, Joanna; Craig Chinault, A.; Beaudet, Arthur L.; Eng, Christine M. (September 2008). "Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization". Human Mutation. 29 (9): 1100–1107. doi:10.1002/humu.20841. PMID 18752307. S2CID 21437006. Li, Xihua; Zhao, Lei; Zhou, Shuizhen; Hu, Chaoping; Shi, Yiyun; Shi, Wei; Li, Hui; Liu, Fang; Wu, Bingbing; Wang, Yi (2015). "A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China". Orphanet Journal of Rare Diseases. 10 (1): 5. doi:10.1186/s13023-014-0220-7. PMC 4323212. PMID 25612904.
All except the Acela, Northeast Regional and Vermonter originate and terminate at Penn Station. Amtrak normally uses tracks 5–12 alongside New Jersey Transit and shares tracks 13–16 with the LIRR and NJ Transit.
==== 4.C Acyl CoA ligase-coupled transporters ==== 4.C.1 The Proposed Fatty Acid Transporter (FAT) Family 4.C.2 The Carnitine O-Acyl Transferase (CrAT) Family 4.C.3 The Acyl-CoA Thioesterase (AcoT) Family
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.